Skip to main content
OpenTrials

Clinical trial condition

Immunoproliferative Disorders

Explore clinical trials studying Immunoproliferative Disorders. Study availability and eligibility vary by location and protocol.

10,001 public trials 2,038 recruiting studies
Refine in advanced search Browse all conditions

Immunoproliferative Disorders trial results

Active, not recruiting

A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies

NCT05362773

Conditions
Blastic Plasmacytoid Dendritic Cell Neoplasm, Bone Marrow Diseases, Chronic Disease, +37 more
Locations
  • Colorado Blood Cancer Network Denver, Colorado, United States
  • University of Maryland, Greenbaum Comprehensive Cancer Center Baltimore, Maryland, United States
  • Dana Farber Cancer Institute Boston, Massachusetts, United States
  • START - Midwest Grand Rapids, Michigan, United States
View Trial Details
Active, not recruiting

Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV and Undergoing Donor Hematopoietic Cell Transplant

NCT02506933

Conditions
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia in Remission, +43 more
Locations
  • City of Hope Medical Center Duarte, California, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
  • M D Anderson Cancer Center Houston, Texas, United States
View Trial Details
Active, not recruiting

SC-PEG Asparaginase vs. Oncaspar in Pediatric Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma

NCT01574274

Conditions
Acute Lymphoblastic Leukemia, Hematologic Diseases, Hemic and Lymphatic Diseases, +10 more
Locations
  • Children's Hospital Boston Boston, Massachusetts, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
  • Columbia University Medical Center, Morgan Stanley Children's Hospital of New York-Presbyterian New York, United States
  • Montefiore Medical Center New York, United States
View Trial Details
Active, not recruiting

Phase 2 Study With Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma (MM) With Upfront Daratumumab-based Therapy

NCT04140162

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • University of Michigan Rogel Cancer Center Ann Arbor, Michigan, United States
  • Barbara Ann Karmanos Cancer Institute Detroit, Michigan, United States
  • University of Rochester Rochester, New York, United States
  • University of Texas Southwestern -- Simmons Comprehensive Cancer Center Dallas, Texas, United States
View Trial Details
Active, not recruiting

Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

NCT03155620

Conditions
Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma, +99 more
Locations
  • Children's Hospital of Alabama Birmingham, Alabama, United States
  • Providence Alaska Medical Center Anchorage, Alaska, United States
  • Banner Children's at Desert Mesa, Arizona, United States
  • Phoenix Childrens Hospital Phoenix, Arizona, United States
View all 172 locations
View Trial Details
Active, not recruiting

Phase II Palbociclib +Ibrutinib in Mantle Cell Lymphoma

NCT03478514

Conditions
B Cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +10 more
Locations
  • City of Hope National Medical Center Duarte, California, United States
  • University of Maryland, Greenebaum Comprehensive Cancer Center Baltimore, Maryland, United States
  • Massachusetts General Hospital Boston, Massachusetts, United States
  • St. Joseph Mercy Hospital Cancer Care Center Ypsilanti, Michigan, United States
View Trial Details
Active, not recruiting

A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL

NCT02970318

Conditions
Chronic Disease, Chronic Lymphocytic Leukemia, Disease Attributes, +14 more
Locations
  • Research Site Chandler, Arizona, United States
  • Research Site Oxnard, California, United States
  • Research Site Athens, Georgia, United States
  • Research Site Joliet, Illinois, United States
View all 157 locations
View Trial Details
Active, not recruiting

A Study of AAV2-hAQP1 Gene Therapy in Participants With Radiation-Induced Late Xerostomia

NCT05926765

Conditions
Grade 2 and 3 Late Xerostomia Caused by Radiotherapy for Cancers of the Upper Aerodigestive Tract, Excluding the Parotid Glands, Hemic and Lymphatic Diseases, Immune System Diseases, +8 more
Locations
  • Banner MD Anderson Cancer Center Gilbert, Arizona, United States
  • City of Hope Duarte, California, United States
  • Miami Cancer Institute at Baptist Health South Florida Miami, Florida, United States
  • University of Iowa Iowa City, Iowa, United States
View all 33 locations
View Trial Details
Active, not recruiting

FDG PET Evaluation for Marginal Zone Lymphoma and Its Prognostic Role

NCT04333524

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations
  • CHU de Dijon Dijon, France
  • Saint Louis Hospital Paris, France
  • IUCT Oncopole Toulouse Toulouse, France
  • ASO SS. Antonio e Biagio e C. Arrigo Alessandria, AL, Italy
View all 25 locations
View Trial Details

Related conditions